⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266113 | 0.82 | — | — | |
| SCHEMBL960906 | 0.80 | LMNA (0.42) | — | |
| SCHEMBL7873024 | 0.79 | — | — | |
| SCHEMBL4810939 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL18419952 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL4643412 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL9015772 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL749270 | 0.78 | LMNA (0.46) | — | |
| SCHEMBL1668231 | 0.77 | — | — | |
| SCHEMBL22444499 | 0.77 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024053650-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST DIACYLGLYCEROL KINASE α AND/OR ζ, AND PHARMACEUTICAL USE THEREOF | 小野薬品工業株式会社 | 2024-03-14 | — | — | WO | disclosed |
| CN-108495852-B | 2-amido thiazole derivatives, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2968345-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002212-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-01-07 | — | — | US | disclosed |
| WO-2014164942-A1 | DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-1908466-B1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2014-02-19 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20050020710-A1 | Hybrid onium salt | WAKO PURE CHEMICALS INDUSTRIES, LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443042-A1 | HYBRID ONIUM SALT | Wako Pure Chemical Industries, Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6410587-B1 | FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS | NEORX CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1998046588-A2 | COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES | NEORX CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |